Managers / Q1 2019 · view latest →
CVI Holdings, LLC
CIK 0001728194 · ONE COMMERCE CENTER, 1201 N. ORANGE STREET, SUITE 715, WILMINGTON, DE, 19801 · 6106172600
Summary
Cvi Holdings, LLC reported $106M in U.S.-listed holdings across 58 positions for Q1 2019.
Its largest position, Nanostring Technologies, represents 17.5% of the portfolio.
Compared with Q4 2018, the fund opened 27 new positions and exited 11.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 49.8% · $53M
- US DOMESTIC · 22.4% · $24M
- Other · 18.7% · $20M
- ADR · 9.1% · $10M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2018 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| NANOSTRING TECHNOLOGIES INC | NEW | +774.1K | 774.1K | +$19M | $19M |
| BLUEPRINT MEDICINES CORP | NEW | +200.0K | 200.0K | +$16M | $16M |
| GNFTYGENFIT S A | NEW | +400.0K | 400.0K | +$10M | $10M |
| EYEPOINT PHARMACEUTICALS INC | NEW | +1.48M | 1.48M | +$3M | $3M |
| AEGLEA BIOTHERAPEUTICS INC | NEW | +271.5K | 271.5K | +$2M | $2M |
| TITAN MED INC | NEW | +762.4K | 762.4K | +$2M | $2M |
| VTV THERAPEUTICS INC | NEW | +1.23M | 1.23M | +$2M | $2M |
| ORAGENICS INC | NEW | +3.39M | 3.39M | +$2M | $2M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | NANOSTRING TECHNOLOGIES INC | COM | 17.54% | $19M | 774.1K |
| 2 | BLUEPRINT MEDICINES CORP | COM | 15.16% | $16M | 200.0K |
| 3 | TIMKENSTEEL CORP | NOTE 6.000% 6/0 | 11.55% | $12M | 10.46M |
| 4 | ANI PHARMACEUTICALS INC | NOTE 3.000%12/0 | 9.36% | $10M | 9.00M |
| 5 | GNFTYGENFIT S Ahistory → | ADS | 9.09% | $10M | 400.0K |
| 6 | AXOVANT SCIENCES LTD | COM | 7.73% | $8M | 6.14M |
| 7 | EROS INTL PLC | SHS NEW | 4.32% | $5M | 498.9K |
| 8 | EYEPOINT PHARMACEUTICALS INC | COM | 2.52% | $3M | 1.48M |
| 9 | AEGLEA BIOTHERAPEUTICS INC | COM | 2.07% | $2M | 271.5K |
| 10 | TITAN MED INC | COM NEW | 2.02% | $2M | 762.4K |
| 11 | VTV THERAPEUTICS INC | CL A | 1.99% | $2M | 1.23M |
| 12 | ORAGENICS INC | COM PAR | 1.88% | $2M | 3.39M |
| 13 | KOPNKOPIN CORPhistory → | COM | 1.76% | $2M | 1.38M |
| 14 | VASCULAR BIOGENICS LTD | COM | 1.57% | $2M | 1.09M |
| 15 | SENSEONICS HLDGS INC | NOTE 5.250% 2/0 | 1.51% | $2M | 1.50M |
| 16 | ADVAXIS INC | COM NEW | 1.18% | $1M | 210.6K |
| 17 | MATINAS BIOPHARMA HLDGS INC | COM | 0.94% | $991,000 | 909.6K |
| 18 | MNKDMANNKIND CORP | COM NEW | 0.86% | $908,000 | 461.1K |
| 19 | BEASLEY BROADCAST GROUP INC | CL A | 0.85% | $894,000 | 224.7K |
| 20 | CO DIAGNOSTICS INC | COM | 0.71% | $751,000 | 708.6K |
| 21 | APTEVO THERAPEUTICS INC | COM | 0.67% | $703,000 | 780.7K |
| 22 | ELECTRAMECCANICA VEHS CORP | COM NEW | 0.66% | $693,000 | 194.7K |
| 23 | AURYN RES INC | COM | 0.64% | $679,000 | 468.6K |
| 24 | MERSANA THERAPEUTICS INC | COM | 0.42% | $442,000 | 84.0K |
| 25 | HEAT BIOLOGICS INC | COM NEW | 0.42% | $440,000 | 346.6K |
| 26 | LQDALIQUIDIA TECHNOLOGIES INC | COM | 0.31% | $330,000 | 29.0K |
| 27 | CHMACHIASMA INC | COM | 0.30% | $321,000 | 61.8K |
| 28 | MOLECULIN BIOTECH INC | COM | 0.28% | $294,000 | 362.7K |
| 29 | PHIO PHARMACEUTICALS CORP | COM | 0.26% | $272,000 | 604.9K |
| 30 | SHSPSHARPSPRING INC | COM | 0.23% | $242,000 | 15.1K |
| 31 | SIGMA LABS INC | *W EXP 02/15/202 | 0.12% | $129,000 | 199.8K |
| 32 | IMV INC | COM | 0.11% | $119,000 | 29.7K |
| 33 | INVIVO THERAPEUTICS HLDGS CO | COM PAR | 0.11% | $116,000 | 74.6K |
| 34 | AILERON THERAPEUTICS INC | COM | 0.10% | $110,000 | 56.6K |
| 35 | THERAPIX BIOSCIENCES LTD | SPONSORED ADS NE | 0.09% | $98,000 | 31.4K |
| 36 | NOVAN INC | COM | 0.06% | $68,000 | 71.5K |
| 37 | ICCCIMMUCELL CORP | COM PAR | 0.06% | $64,000 | 10.0K |
| 38 | ACASTI PHARMA INC | CL A NEW | 0.06% | $63,000 | 61.5K |
| 39 | CHECK CAP LTD | *W EXP 05/03/202 | 0.05% | $52,000 | 136.4K |
| 40 | VALERITAS HLDGS INC | COM NEW | 0.03% | $35,000 | 106.8K |
| 41 | MEDIGUS LTD | *W EXP 07/23/202 | 0.03% | $29,000 | 64.3K |
| 42 | SEANERGY MARITIME HLDGS CORP | *W EXP 11/10/202 | 0.03% | $27,000 | 1.18M |
| 43 | BIONDVAX PHARMACEUTICALS LTD | *W EXP 05/15/202 | 0.02% | $25,000 | 72.8K |
| 44 | NEOVASC INC | COM NEW | 0.02% | $21,000 | 50.8K |
| 45 | IMMURON LTD | *W EXP 05/12/202 | 0.01% | $15,000 | 10.9K |
| 46 | FLEXSHOPPER INC | *W EXP 09/28/202 | 0.01% | $14,000 | 50.0K |
| 47 | AMERI HLDGS INC | *W EXP 11/08/202 | 0.01% | $8,000 | 99.5K |
| 48 | FUELCELL ENERGY INC | COM NEW | 0.01% | $8,000 | 33.3K |
| 49 | ONCONOVA THERAPEUTICS INC | *W EXP 07/11/202 | 0.01% | $7,000 | 132.2K |
| 50 | CREATIVE REALITIES INC | *W EXP 11/09/202 | 0.01% | $6,000 | 15.0K |
| 51 | BENITEC BIOPHARMA LTD | *W EXP 08/14/202 | 0.01% | $6,000 | 50.0K |
| 52 | SOLIGENIX INC | *W EXP 11/14/202 | 0.00% | $2,000 | 16.6K |
| 53 | MYND ANALYTICS INC | *W EXP 06/29/202 | 0.00% | $1,000 | 13.7K |
| 54 | APPLIED DNA SCIENCES INC | *W EXP 11/21/201 | 0.00% | $1,000 | 31.4K |
| 55 | CYTORI THERAPEUTICS INC | *W EXP 05/28/202 | 0.00% | $1,000 | 259.2K |
| 56 | CELLECT BIOTECHNOLOGY LTD | *W EXP 08/03/202 | 0.00% | $1,000 | 12.5K |
| 57 | INSPIREMD INC | *W EXP 03/14/202 | 0.00% | $0 | 48.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q2 2024 | $116M | 144 | Aug 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $106M | 157 | May 7, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $48M | 187 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $51M | 229 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $95M | 277 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $266M | 413 | May 16, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $784M | 615 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $1.3B | 882 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $1.4B | 930 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $1.5B | 928 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $1.5B | 948 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $1.6B | 899 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $1.5B | 790 | Aug 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $1.4B | 615 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $536M | 182 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $246M | 83 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $270M | 70 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $28M | 37 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $71M | 36 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019REVEALED | $131M | 107 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019REVEALED | $172M | 118 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $106M | 58 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $45M | 42 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 2 additional managers.
- HEIGHTS CAPITAL MANAGEMENT, INC028-13218
- CVI Investments, Inc.028-17822
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.